TSH Biopharm
Taipei, Taiwan· Est.
Taiwan biotech delivering liquid‑biopsy diagnostics and a first‑in‑class presbyopia therapeutic.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan biotech delivering liquid‑biopsy diagnostics and a first‑in‑class presbyopia therapeutic.
OphthalmologyOncology
Technology Platform
Liquid‑biopsy diagnostic platform for minimally invasive cancer detection and a novel ophthalmic drug delivery system targeting presbyopia.
Opportunities
Growing demand for non‑invasive cancer diagnostics and an aging population seeking presbyopia treatments present sizable market opportunities.
Risk Factors
Clinical trial failures, regulatory hurdles, and competition from established diagnostic and ophthalmic drug manufacturers could impede commercialization.
Competitive Landscape
TSH competes with global liquid‑biopsy firms and ophthalmic drug developers; its integrated diagnostics‑therapeutics model and Taiwan‑first presbyopia drug provide differentiation.